Stifel Nicolaus is out with its report today on Amgen AMGN, maintaining Buy.
In its report, Stifel Nicolaus writes, "To value Amgen we relied upon a DCF analysis, using our updated bottom-up, market-based model and its related adjusted EBIT,
resulting in our one-year target price of $67. We continue to view Amgen's valuation as attractive and maintain our Buy rating."
At the time of posting, shares of AMGN were trading pre-market at $55.00, up 0.55% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in